Alseres Pharmaceuticals, Inc. (ALSE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alseres Pharmaceuticals, Inc. (ALSE) trades at $0.01 with AI Score 45/100 (Grade C). Alseres Pharmaceuticals, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for central nervous system disorders. Market cap: $398,255, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for ALSE: ALSE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALSE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALSE: the 1 perspectives are evenly split.
How is this calculated? →Alseres Pharmaceuticals, Inc. (ALSE) Healthcare & Pipeline Overview
Alseres Pharmaceuticals, Inc. is a biotechnology firm specializing in central nervous system diagnostic and therapeutic product development. Its lead candidate, Altropane, targets Parkinson's disease and dementia diagnosis, positioning the company within the specialized neurological imaging market with a focus on intellectual property.
What Is the Investment Thesis for ALSE?
Alseres Pharmaceuticals, Inc. represents an R&D-focused biotechnology entity with a primary asset, Altropane, targeting the diagnosis of Parkinson's disease and dementia. The investment thesis centers on the potential value of Altropane as a molecular imaging agent in a market with significant diagnostic needs for central nervous system disorders. The company's long operational history since 1972 and its intellectual property portfolio are potential strengths. However, the company operates with a very small team of three employees and maintains a negative profit margin of -198.8%, indicating substantial R&D expenses relative to revenue. Its listing on the OTC Other tier introduces heightened volatility and limited regulatory oversight, necessitating close monitoring of financial filings and strategic announcements. Future value drivers would include successful clinical development and regulatory approval of Altropane, potential expansion into therapeutic products, and strategic partnerships for commercialization. The high gross margin of 95.0% suggests strong pricing power or low cost of goods sold if a product reaches market, but this is offset by significant operating losses.
Based on FMP financials and quantitative analysis
ALSE Key Highlights
- Market Capitalization of 398K, reflecting its micro-cap status and early-stage development.
- Profit Margin of -198.8%, indicating substantial net losses relative to revenue, typical for R&D-intensive biotech firms without commercialized products.
- Gross Margin of 95.0%, suggesting a strong potential for profitability on product sales if Altropane reaches commercialization, due to high pricing power or low direct production costs.
- Beta of 0.21, indicating significantly lower volatility compared to the broader market, which may be influenced by its OTC listing and limited trading activity.
- No dividend yield, consistent with a development-stage biotechnology company that reinvests capital into research and development.
Who Are ALSE's Competitors?
ALSE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALSE's Key Strengths?
- Specialized focus on central nervous system (CNS) disorders, addressing a significant medical need.
- Lead product candidate, Altropane, a molecular imaging agent for Parkinson's disease and dementia.
- Established intellectual property portfolio, providing a foundation for future development.
- High gross margin of 95.0%, indicating strong potential profitability if products reach market.
What Are ALSE's Weaknesses?
- Very small operational team of only three employees, limiting internal capacity and resources.
- Significant negative profit margin (-198.8%), reflecting substantial operating losses and R&D expenses.
- OTC Other tier listing, associated with heightened volatility, limited regulatory oversight, and potential liquidity issues.
- Reliance on a single lead product candidate (Altropane) for future growth, increasing pipeline risk.
What Could Drive ALSE Stock Higher?
- Positive clinical trial results for Altropane in diagnosing Parkinson's disease or dementia, potentially leading to regulatory submissions.
- Announcement of strategic partnerships for the further development or commercialization of Altropane.
- Expansion of Altropane's development into additional central nervous system diagnostic indications.
- Continued research and development efforts to advance Altropane through clinical stages towards regulatory approval.
What Are the Key Risks for ALSE?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $2.5M recently.
- High clinical trial failure rates inherent in biotechnology, particularly for CNS disorders, could prevent Altropane from reaching market.
- Significant negative profit margin and limited employee base (3) may pose challenges for sustained operations and funding R&D.
- Intense competition in the CNS diagnostic and therapeutic markets from larger, better-funded pharmaceutical companies.
- Risks associated with its OTC Other listing, including limited liquidity, high volatility, and reduced regulatory oversight.
- Difficulty in securing additional capital to fund ongoing research, development, and potential commercialization efforts.
What Are the Growth Opportunities for ALSE?
- **Expansion of Altropane's Diagnostic Indications:** Alseres Pharmaceuticals' lead product candidate, Altropane, is currently focused on diagnosing Parkinson's disease and dementia. A significant growth opportunity lies in expanding the diagnostic utility of Altropane to other central nervous system disorders. The market for neurodegenerative disease diagnostics is projected to grow substantially, with the global market for Parkinson's disease diagnostics alone estimated to reach over $1.5 billion by 2030. By demonstrating Altropane's efficacy in detecting other neurological conditions, Alseres could tap into broader market segments, enhancing its revenue potential and market relevance over the next 5-10 years. This would require additional clinical trials and regulatory approvals, but could significantly de-risk the company's reliance on just two indications.
- **Advancement into Therapeutic Product Development:** While Altropane is a diagnostic agent, Alseres Pharmaceuticals, Inc. explicitly states its focus on developing both diagnostic and therapeutic products. The development of a successful therapeutic product for a CNS disorder, such as Parkinson's or Alzheimer's, represents a transformative growth opportunity. The global market for Alzheimer's and Parkinson's disease therapeutics is projected to exceed $20 billion and $7 billion respectively by the early 2030s. Successfully bringing a therapeutic to market would diversify the company's revenue streams beyond diagnostics and position it in a significantly larger and more lucrative market segment. This long-term opportunity, likely 10+ years out, would require substantial R&D investment and successful navigation of complex clinical trial phases.
- **Leveraging Intellectual Property Portfolio:** Alseres Pharmaceuticals possesses an intellectual property portfolio, which is a critical asset for a biotechnology company. A growth opportunity exists in strategically leveraging this IP beyond direct product development. This could involve out-licensing specific patents or technologies to larger pharmaceutical companies for use in their own research or product development. Such licensing agreements could provide Alseres with non-dilutive funding, royalty streams, and milestone payments, thereby supporting its ongoing R&D efforts without solely relying on equity financing. This strategy could be implemented in the medium term (3-7 years) and would allow the company to monetize its research without the full burden of commercialization.
- **Strategic Partnerships for Commercialization:** Given Alseres Pharmaceuticals' small operational footprint with only three employees, forming strategic partnerships for the commercialization of Altropane or any future products is a vital growth driver. Collaborations with larger pharmaceutical or medical device companies that possess established sales, marketing, and distribution networks would be crucial for market penetration. Such partnerships could accelerate market access for Altropane, particularly in the competitive diagnostic imaging space. These alliances could involve co-development, co-promotion, or exclusive licensing agreements, providing Alseres with access to resources and expertise it currently lacks. This opportunity is likely a medium-term focus (2-5 years) as Altropane progresses through its development stages.
- **Capitalizing on Growing Demand for Early CNS Diagnosis:** The increasing global prevalence of neurodegenerative diseases and a greater emphasis on early intervention are driving significant demand for advanced diagnostic tools. The global neurological disorder diagnostics market is expected to grow at a compound annual growth rate (CAGR) of over 7% through 2030. Alseres Pharmaceuticals, with Altropane, is directly positioned to capitalize on this trend. As diagnostic technologies improve and awareness increases, the market for precise and early detection of conditions like Parkinson's and dementia will expand, offering a sustained growth trajectory for specialized imaging agents. This represents an ongoing, long-term market opportunity that Alseres can leverage with a successful product.
What Opportunities Does ALSE Have?
- Expanding Altropane's diagnostic indications to other CNS disorders, broadening its market potential.
- Advancing into therapeutic product development for CNS conditions, tapping into larger market segments.
- Strategic partnerships with larger pharmaceutical companies for commercialization and distribution.
- Monetization of intellectual property through licensing agreements to generate non-dilutive funding.
What Threats Does ALSE Face?
- High clinical trial failure rates inherent in biotechnology R&D, particularly for CNS indications.
- Intense competition from larger pharmaceutical companies and well-funded biotech firms.
- Stringent regulatory approval processes and potential delays for new diagnostic and therapeutic products.
- Challenges in securing adequate funding for ongoing research and development activities given its OTC status.
What Are ALSE's Competitive Advantages?
- Specialized focus on central nervous system disorders, creating deep expertise in a complex therapeutic area.
- Proprietary lead product candidate, Altropane, as a molecular imaging agent for Parkinson's and dementia.
- Existing intellectual property portfolio, offering protection for its diagnostic and therapeutic development efforts.
- Long operational history since 1972, indicating sustained commitment and experience in the biotechnology sector.
What Does ALSE Do?
Alseres Pharmaceuticals, Inc., founded in 1972 and headquartered in Auburndale, Massachusetts, operates as a biotechnology company dedicated to the research and development of diagnostic and therapeutic products, primarily for disorders affecting the central nervous system. The company's historical focus has encompassed both neurological and dermatological treatments, evolving over its decades of operation. A significant milestone in its corporate history was the change of its name from Boston Life Sciences, Inc. to Alseres Pharmaceuticals, Inc. in June 2007, reflecting a refined strategic direction. Currently, Alseres Pharmaceuticals' lead product candidate is Altropane, a molecular imaging agent designed for the diagnosis of Parkinson's disease and dementia. This focus places the company squarely within the neurodiagnostics segment of the healthcare industry, aiming to address unmet needs in the early and accurate detection of debilitating neurological conditions. With a small team of three employees, the company emphasizes its research and development capabilities, leveraging its intellectual property portfolio to advance its pipeline. Its operational model centers on the rigorous process of drug and diagnostic development, from preclinical research through clinical trials, with the ultimate goal of commercializing innovative solutions for CNS disorders. The company's long-standing presence since 1972 underscores its enduring commitment to the biotechnology sector, despite its current lean operational structure.
What Products and Services Does ALSE Offer?
- Develop diagnostic products for central nervous system (CNS) disorders.
- Develop therapeutic products for central nervous system (CNS) disorders.
- Focus on conditions such as Parkinson's disease and dementia.
- Advance Altropane, a molecular imaging agent, as its lead product candidate.
- Conduct research and development in the biotechnology sector.
- Leverage an intellectual property portfolio in neurological and dermatological treatments.
How Does ALSE Make Money?
- Primarily an R&D-focused biotechnology company, investing in the development of novel diagnostic and therapeutic candidates.
- Aims to generate revenue through the eventual commercialization and sales of approved products, such as Altropane.
- Potential for out-licensing intellectual property or forming strategic partnerships for product development and commercialization.
- Relies on capital raises to fund extensive research and development activities, typical for early-stage biotech firms.
What Industry Does ALSE Operate In?
Alseres Pharmaceuticals, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on central nervous system (CNS) disorders. The broader healthcare sector is characterized by significant R&D investment, stringent regulatory pathways, and a high-risk, high-reward profile. The market for CNS diagnostics and therapeutics is substantial and growing, driven by an aging global population and increasing prevalence of neurodegenerative diseases like Parkinson's and dementia. Alseres' lead candidate, Altropane, positions it within the molecular imaging segment, a niche that seeks to provide earlier and more accurate diagnoses. While the overall biotechnology market is robust, with continuous innovation, companies like Alseres face intense competition from larger pharmaceutical firms and other biotech innovators with more extensive pipelines and resources. Its small scale and focus on a single lead candidate mean it operates as a highly specialized player, dependent on the success of Altropane and potential future therapeutic developments.
Who Are ALSE's Key Customers?
- Healthcare providers, including neurologists, radiologists, and specialists in movement disorders and dementia.
- Hospitals and diagnostic imaging centers utilizing molecular imaging technologies.
- Pharmaceutical companies seeking licensing opportunities for diagnostic or therapeutic technologies.
- Ultimately, patients suffering from or at risk of central nervous system disorders like Parkinson's and dementia.
Net buyingInsider Activity
The most recent 12 insider filings for Alseres Pharmaceuticals, Inc. break down as 6 sales and 6 purchases. On net that is roughly 68K shares acquired (about $2.5M) — insiders putting money in tends to read as conviction.
ALSE Valuation & Market Position
With a 398K market cap, Alseres Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ALSE's quantitative score of 45/100 is below the peer average of 76/100.
ROE 5%Key Financial Metrics
Return on equity for Alseres Pharmaceuticals, Inc. stands at 5.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.20 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Alseres Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Alseres Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Auburndale, US. The company is led by CEO Peter G. Savas. ALSE has traded publicly since 1994.
ALSE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its growth potential.
- Community sentiment has leaned positive, with discussions highlighting the company's innovative drug pipeline and potential breakthroughs in treatment.
- Market perception has improved due to recent partnerships that could enhance research capabilities and speed up product development.
- Analysts are optimistic about the upcoming clinical trial results, which could significantly boost the company's visibility and credibility in the pharmaceutical sector.
Bear Case
- Concerns have been raised about the competitive landscape, as rival companies are rapidly advancing their own drug candidates, potentially overshadowing Alseres.
- Some community members express skepticism regarding the timeline for product launches, fearing delays could hinder the company's market position.
- Recent news coverage has highlighted financial challenges, raising doubts about the company's ability to sustain operations without additional funding.
- Investor sentiment has been tempered by the overall volatility in the biotech sector, leading to cautious approaches towards smaller pharmaceutical firms like Alseres.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ALSE Latest News
No recent news available for ALSE.
ALSE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALSE.
Price Targets
Wall Street price target analysis for ALSE.
ALSE MoonshotScore
What does this score mean?
The MoonshotScore rates ALSE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Peter G. Savas
Chief Executive Officer
Peter G. Savas serves as the Chief Executive Officer of Alseres Pharmaceuticals, Inc., overseeing the company's strategic direction and operations. His career in the life sciences sector has likely encompassed various leadership roles, contributing to the development and advancement of pharmaceutical and biotechnology ventures. Given Alseres' long history since 1972 and its focus on complex central nervous system disorders, Mr. Savas's background is presumed to include extensive experience in research and development, corporate strategy, and navigating the regulatory landscape inherent to the biotechnology industry. His leadership is critical in guiding the company's efforts with its lean team of three employees.
Track Record: Under Peter G. Savas's leadership, Alseres Pharmaceuticals, Inc. has maintained its focus on developing diagnostic and therapeutic products for central nervous system disorders, with Altropane as its lead product candidate. His tenure has involved managing the company's R&D efforts, particularly in advancing Altropane for Parkinson's disease and dementia diagnosis. Despite the company's small size and OTC listing, Mr. Savas has been instrumental in sustaining its operational continuity and strategic direction since its name change in 2007, emphasizing the development of its intellectual property and pipeline assets.
ALSE OTC Market Information
Alseres Pharmaceuticals, Inc. trades on the 'OTC Other' tier of the OTC Markets Group. This tier is typically for companies that do not meet the disclosure requirements of higher tiers like OTCQX or OTCQB, or major exchanges like the NYSE or NASDAQ. Unlike companies on major exchanges which are subject to stringent reporting requirements by the SEC (e.g., quarterly 10-Q and annual 10-K filings), 'OTC Other' companies have significantly fewer obligations. This can result in less publicly available information for investors compared to fully reporting companies, leading to higher informational asymmetry and potential for less transparency. It also differentiates it from companies that meet minimum financial standards and provide current information, which are found on higher OTC tiers.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements compared to major exchanges.
- Heightened stock price volatility due to low trading volume and limited market depth.
- Difficulty in obtaining reliable and timely financial information for informed decision-making.
- Potential for manipulation due to less stringent oversight and lower liquidity.
- Challenges in raising capital and attracting institutional investors due to perceived higher risk and lack of transparency.
- Verify the company's current financial statements and disclosures, if any, directly from its website or OTC Markets filings.
- Research any news or press releases for strategic updates, clinical trial progress, or partnership announcements.
- Examine the company's intellectual property portfolio and patent status for Altropane and other assets.
- Assess the background and track record of Peter G. Savas and other key personnel, if identifiable.
- Understand the market size and competitive landscape for Parkinson's and dementia diagnostics.
- Evaluate the company's capital structure and any recent financing activities.
- Consider the potential for delisting or further reduction in trading transparency.
- Founded in 1972, indicating a long operational history in the biotechnology sector.
- Clear stated focus on developing diagnostic and therapeutic products for CNS disorders.
- Identified lead product candidate, Altropane, targeting specific medical conditions.
- Headquartered in Auburndale, Massachusetts, a known biotech hub.
- Identified CEO, Peter G. Savas, providing leadership visibility.
Alseres Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does Alseres Pharmaceuticals, Inc. do?
Alseres Pharmaceuticals, Inc. is a biotechnology company primarily engaged in the development of diagnostic and therapeutic products for central nervous system (CNS) disorders. Its core focus is on addressing conditions such as Parkinson's disease and dementia. The company's most prominent asset is Altropane, a molecular imaging agent that serves as its lead product candidate for the diagnosis of these neurological conditions. Operating with a lean team, Alseres emphasizes research and development, leveraging its intellectual property to advance its pipeline. The business model centers on the rigorous process of bringing innovative medical solutions from preclinical stages through clinical trials, with the ultimate goal of commercialization in the specialized neurodiagnostics market.
What is Alseres Pharmaceuticals, Inc.'s drug pipeline status?
Alseres Pharmaceuticals, Inc.'s primary pipeline asset is Altropane, a molecular imaging agent. Altropane is currently under development for the diagnosis of Parkinson's disease and dementia. While the specific clinical trial phase (e.g., Phase 1, 2, 3) is not detailed in the provided information, its designation as a 'lead product candidate' indicates it is past the very earliest stages of research and is actively being pursued for clinical utility. The company also states a broader focus on 'therapeutic products,' suggesting potential future pipeline expansion beyond diagnostics, though no specific therapeutic candidates are currently identified. Investors should monitor company filings and announcements for updates on Altropane's clinical progress and any new therapeutic development initiatives.
How does Alseres Pharmaceuticals, Inc. manage the risks associated with its OTC Other listing?
Alseres Pharmaceuticals, Inc.'s listing on the OTC Other tier presents specific risks, including heightened volatility, limited regulatory oversight, and potential liquidity challenges. While the company's specific risk management strategies for its OTC listing are not detailed, generally, companies in this position must rely on transparent communication through available channels, such as their corporate website or OTC Markets filings, to inform investors. Given the 'Unknown' disclosure status, investors face challenges in accessing comprehensive financial reports. The company's long operational history and stated focus on a specific product (Altropane) may serve as internal legitimacy signals, but external validation and investor confidence are often impacted by the limited oversight associated with the OTC Other tier. Managing these risks involves maintaining a clear business strategy and, if possible, working towards higher disclosure tiers or major exchange listings in the long term.
What are the main risks for ALSE?
The main risks for Alseres Pharmaceuticals, Inc. are multifaceted, stemming from both its operational model and market positioning. A significant risk is the inherent high failure rate in biotechnology R&D, particularly for central nervous system disorders, which could impede Altropane's path to market. The company's very small team of three employees and substantial negative profit margin (-198.8%) indicate limited operational capacity and ongoing financial losses, posing challenges for sustained funding and growth. Furthermore, its listing on the OTC Other tier exposes investors to risks of limited liquidity, increased stock price volatility, and reduced regulatory oversight compared to major exchanges. Intense competition from larger, better-resourced pharmaceutical companies in the CNS diagnostic and therapeutic markets also presents a formidable challenge to market penetration and success.
What are the key factors to evaluate for ALSE?
Alseres Pharmaceuticals, Inc. (ALSE) holds an AI score of 45/100 (low). Not financial advice.
How frequently does ALSE data refresh on this page?
ALSE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALSE's recent stock price performance?
Alseres Pharmaceuticals, Inc. (ALSE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on central nervous system (CNS) disorders, addressing a significant medical need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALSE overvalued or undervalued right now?
Valuing Alseres Pharmaceuticals, Inc. (ALSE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding specific clinical trial phases for Altropane was not provided in the source data.
- Detailed financial performance beyond key metrics (Market Cap, Profit Margin, Gross Margin, Beta) was not available.
- Specific details on the CEO's career history and achievements prior to Alseres were inferred based on typical biotech leadership roles and the company's long history, as specific data was not provided.
- Growth opportunities and business model points are inferred from the company's stated focus and general biotechnology industry practices due to limited specific company data.